Kodiak Sciences

KOD

Market cap $1.97B

KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.

PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.

KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.

PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.

Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies.

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

The small-cap Russell 2000 punched through to an intraday record high on Friday, capping a furious 13-day rally that marks the index's best run since 2020 and signaling that gains are finally broadening beyond the mega-cap tech leaders.

KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.

PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.

Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fueled by robust Phase 3 GLOW2 results for Zenkuda (tarcocimab), an experimental treatment aimed at retinal vascular disorders.